Advertisement
UK markets close in 11 minutes
  • FTSE 100

    8,139.78
    +60.92 (+0.75%)
     
  • FTSE 250

    19,828.99
    +227.01 (+1.16%)
     
  • AIM

    754.84
    +1.72 (+0.23%)
     
  • GBP/EUR

    1.1662
    +0.0005 (+0.04%)
     
  • GBP/USD

    1.2452
    -0.0059 (-0.47%)
     
  • Bitcoin GBP

    51,123.74
    +173.19 (+0.34%)
     
  • CMC Crypto 200

    1,330.32
    -66.21 (-4.75%)
     
  • S&P 500

    5,099.45
    +51.03 (+1.01%)
     
  • DOW

    38,179.34
    +93.54 (+0.25%)
     
  • CRUDE OIL

    83.67
    +0.10 (+0.12%)
     
  • GOLD FUTURES

    2,345.30
    +2.80 (+0.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,166.11
    +248.83 (+1.39%)
     
  • CAC 40

    8,098.92
    +82.27 (+1.03%)
     

AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane

AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane

In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.